Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer therapeutics - Anticancer Bioscience

Next Previous
X
Search
Drug Profile

Research programme: anticancer therapeutics - Anticancer Bioscience

Alternative Names: Research programme: MYC-SL therapeutics - Anticancer Bioscience; Research programme: MYC-synthetic lethal (MYC-SL) therapeutics - Anticancer Bioscience; Research programme: MYC-synthetic lethal anticancer compounds - Anticancer Bioscience

Latest Information Update: 11 Jan 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator J. Michael Bishop Institute of Cancer Research
  • Developer Anticancer Bioscience; J. Michael Bishop Institute of Cancer Research
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cell division inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Oct 2023 Pharmacodynamics and adverse event data from a preclinical trial in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
  • 09 Dec 2021 Anticancer Bioscience in-licenses MYC synthetic lethal anticancer compounds from J. Michael Bishop Institute of Cancer Research
  • 20 Oct 2021 Anticancer Bioscience has patents pending for MYC synthetic lethal anticancer compounds covering both methods and composition of matter

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top